The cGAS‐STING pathway is oncogenic in PTCL, whereas targeting cGAS suppresses tumor growth, and CLK1 may be a sensitivity indicator for cGAS inhibitors. This evidence concerns the gene CLK1 and mature T-cell and NK-cell non-Hodgkin lymphoma.